Trevogrumab

Trevogrumab is a human monoclonal antibody designed for the treatment of muscle atrophy due to orthopedic disuse and sarcopenia. Sometimes it is combined with Garetosmab.
Trevogrumab is a fully human monoclonal antibody that functions as a selective inhibitor of myostatin, a key negative regulator of skeletal muscle growth and mass. By binding and neutralizing myostatin, Trevogrumab prevents its interaction with activin type 2 receptors, thereby reducing myostatin-mediated signaling and allowing increased muscle growth and preservation.
This drug was developed by Regeneron Pharmaceuticals, Inc.